articleJournal of Clinical OncologyOct 21, 2008BRONZE OA

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

BIBrian I. RiniSHSusan HalabiJEJonathan E. RosenbergWMWalter M. StadlerDADaniel A. Vaena

CancerCare Manitoba

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE: Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A prospective, randomized phase III trial of bevacizumab plus IFN versus IFN monotherapy was conducted. PATIENTS AND METHODS: Patients with previously untreated, metastatic clear-cell RCC were randomly assigned to receive either bevacizumab (10 mg/kg intravenously every 2 weeks) plus IFN (9 million U subcutaneously three times weekly) or the same dose and schedule of IFN monotherapy in a multicenter phase III trial. The primary end point was overall survival (OS). Secondary end points…

Citation impact

907
total citations
FWCI
84.40
Percentile
100%
References
29
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Medicine
  • Bevacizumab
  • Internal medicine
  • Renal cell carcinoma
  • Clinical endpoint
  • Hazard ratio
  • Gastroenterology
  • Proteinuria
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding